Trimethobenzamide

CHEMBL1201256 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
388.5 g/mol
LogP
2.3
Phase
4

Trimethobenzamide is an antiemetic agent that acts centrally by blocking dopamine receptors in the chemoreceptor trigger zone of the medulla, thereby suppressing nausea and vomiting. It is used to treat nausea and vomiting associated with various conditions including postoperative states and gastroenteritis, and is sometimes used as adjunctive therapy in Parkinson's disease patients experiencing drug-related nausea. Unlike phenothiazine antiemetics, it has a relatively low risk of extrapyramidal side effects.

Khối lượng phân tử

388,5000 g/mol

LogP

2,30

TPSA

69,30 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC

InChI

InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)

Molecular Formula

C21H28N2O5

HBD / HBA

1 / 6

Liên kết có thể quay

10

Nguyên tử nặng

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Trimethobenzamide is an antiemetic agent that acts centrally by blocking dopamine receptors in the chemoreceptor trigger zone of the medulla, thereby suppressing nausea and vomiting. It is used to treat nausea and vomiting associated with various conditions including postoperative states and gastroenteritis, and is sometimes used as adjunctive therapy in Parkinson's disease patients experiencing drug-related nausea. Unlike phenothiazine antiemetics, it has a relatively low risk of extrapyramidal side effects.

Yes, Trimethobenzamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201256. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5577. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.